Trigger Warning: One to Two Servings of Caffeinated Beverages Not Associated with Higher Risk of Migraine Headaches but Three or More May Trigger Migraines
Lindsey Diaz-MacInnis (BIDMC Communications) 617-667-7372, firstname.lastname@example.org
AUGUST 08, 2019
A disabling neurologic disorder, migraine affects more than one billion adults worldwide.
Anecdotal evidence suggests caffeine can both trigger and alleviate symptoms of migraine, but few rigorous studies have evaluated either claim.
In this prospective cohort study, 98 adults who experience frequent episodic migraine made detailed electronic diary entries twice a day for a minimum of six weeks, providing data about 825 migraines during 4,467 days of observation.
BOSTON – Afflicting more than one billion adults worldwide, migraine is the third most prevalent illness in the world. In addition to severe headache, symptoms of migraine can include nausea, changes in mood, sensitivity to light and sound, as well as visual and auditory hallucinations. People who suffer from migraine report that weather patterns, sleep disturbances, hormonal changes, stress, medications and certain foods or beverages can bring on migraine attacks. However, few studies have evaluated the immediate effects of these suspected triggers.
In a study published today in the American Journal of Medicine, researchers at Beth Israel Deaconess Medical Center (BIDMC), Brigham and Women’s Hospital and the Harvard T.H. Chan School of Public Health (HSPH) evaluated the role of caffeinated beverages as a potential trigger of migraine. Led by Elizabeth Mostofsky, ScD, an investigator in BIDMC’s Cardiovascular Epidemiology Research Unit and a member of the Department of Epidemiology at HSPH, researchers found that, among patients who experience episodic migraine, one to two servings of caffeinated beverages were not associated with headaches on that day, but three or more servings of caffeinated beverages may be associated with higher odds of migraine headache occurrence on that day or the following day.
“While some potential triggers – such as lack of sleep – may only increase migraine risk, the role of caffeine is particularly complex, because it may trigger an attack but also helps control symptoms,” said Mostofsky. “Caffeine’s impact depends both on dose and on frequency, but because there have been few prospective studies on the immediate risk of migraine headaches following caffeinated beverage intake, there is limited evidence to formulate dietary recommendations for people with migraines.”
In their prospective cohort study, Mostofsky and colleagues – including Principal Investigator Suzanne M. Bertisch, MD, MPH, of the Division of Sleep and Circadian Disorders at Brigham and Women’s Hospital, Beth Israel Deaconess Medical Center, and Harvard Medical School – 98 adults with frequent episodic migraine completed electronic diaries every morning and every evening for at least six weeks. Every day, participants reported the total servings of caffeinated coffee, tea, soda and energy drinks they consumed, as well as filled out twice daily headache reports detailing the onset, duration, intensity, and medications used for migraines since the previous diary entry. Participants also provided detailed information about other common migraine triggers, including medication use, alcoholic beverage intake, activity levels, depressive symptoms, psychological stress, sleep patterns and menstrual cycles.
To evaluate the link between caffeinated beverage intake and migraine headache on the same day or on the following day, Mostofsky, Bertisch and colleagues used a self-matched analysis, comparing an individual participant’s incidence of migraines on days with caffeinated beverage intake to that same participant’s incidence of migraines on days with no caffeinated beverage intake. This self-matching eliminated the potential for factors such as sex, age, and other individual demographic, behavioral and environmental factors to confound the data. The researchers further matched headache incidence by day of the week, eliminating weekend versus week day habits that may also impact migraine occurrence.
Self-matching also allowed for the variations in caffeine dose across different types of beverages and preparations.
“One serving of caffeine is typically defined as eight ounces or one cup of caffeinated coffee, six ounces of tea, a 12-ounce can of soda and a 2-ounce can of an energy drink,” said Mostofsky. “Those servings contain anywhere from 25 to 150 milligrams of caffeine, so we cannot quantify the amount of caffeine that is associated with heightened risk of migraine. However, in this self-matched analysis over only six weeks, each participant’s choice and preparation of caffeinated beverages should be fairly consistent.”
Overall, the researchers saw no association between one to two servings of caffeinated beverages and the odds of headaches on the same day, but they did see higher odds of same-day headaches on days with three or more servings of caffeinated beverages. However, among people who rarely consumed caffeinated beverages, even one to two servings increased the odds of having a headache that day.
“Despite the high prevalence of migraine and often debilitating symptoms, effective migraine prevention remains elusive for many patients,” said Bertisch. “This study was a novel opportunity to examine the short-term effects of daily caffeinated beverage intake on the risk of migraine headaches. Interestingly, despite some patients with episodic migraine thinking they need to avoid caffeine, we found that drinking one to two servings/day was not associated with higher risk of headache. More work is needed to confirm these findings, but it is an important first step.”
In addition to Mostofsky and Bertisch, co-authors included, Murray A. Mittleman, MD, DrPH, and Wenyuan Li, ScD, of BIDMC; and Catherine Buettner, MD, of Mount Auburn Hospital.
This work was conducted with support from the National Institute of Neurological Disorders And Stroke (R21-NS091627), the American Sleep Medicine Foundation, Harvard Catalyst | The Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, National Institutes of Health Award UL 1TR002541), and financial contributions from Harvard University and its affiliated academic healthcare centers.
Potential Conflicts of Interest: Dr. Bertisch reports receiving research support from Merck, Sharpe & Dohme, Lockheed Martin (DARPA primary funding source), ApniMed, and has served as a consultant for Verily. Dr. Buettner has received honorarium for consulting for Dr. Reddy Pharmaceutical. All other authors report no disclosures relevant to this manuscript.